Edgewise Therapeutics Inc
EWTX13.170USD
+0.110+0.84%
Cierre 06/27, 16:00（ET）Cotizaciones retrasadas 15 min
1.25BCap. mercado
PérdidaP/E TTM
Más Datos de Edgewise Therapeutics Inc Compañía
Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.
Información de la empresa
Símbolo de cotizaciónEWTX
Nombre de la empresaEdgewise Therapeutics Inc
Fecha de salida a bolsaMar 26, 2021
Fundada en2017
Director ejecutivoDr. Kevin Koch, Ph.D.
Número de empleados110
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 26
Dirección1715 38Th St
CiudadBOULDER
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal80301
Teléfono17202627002
Sitio Webhttps://edgewisetx.com/
Símbolo de cotizaciónEWTX
Fecha de salida a bolsaMar 26, 2021
Fundada en2017
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Kevin Koch, Ph.D.
Dr. Kevin Koch, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
359.40K
+1.74%
Dr. Joanne M. Donovan, M.D., Ph.D.
Dr. Joanne M. Donovan, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
21.49K
+32.17%
Dr. Behrad Derakhshan, Ph.D.
Dr. Behrad Derakhshan, Ph.D.
Chief Operating Officer
Chief Operating Officer
20.36K
+20.89%
Dr. Badreddin Edris, Ph.D.
Dr. Badreddin Edris, Ph.D.
Independent Director, Co-Founder
Independent Director, Co-Founder
19.82K
--
Dr. Jonathan D. (Jon) Root, M.D.
Dr. Jonathan D. (Jon) Root, M.D.
Independent Director
Independent Director
15.63K
--
Dr. Jonathan C. Fox, M.D., Ph.D.
Dr. Jonathan C. Fox, M.D., Ph.D.
Independent Director
Independent Director
11.42K
+5.15%
Mr. John R. Moore
Mr. John R. Moore
General Counsel
General Counsel
1.34K
--
Dr. Alan Russell, Ph.D.
Dr. Alan Russell, Ph.D.
Chief Scientific Officer, Director, Co-Founder
Chief Scientific Officer, Director, Co-Founder
--
--
Mr. R. Michael Carruthers
Mr. R. Michael Carruthers
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Kevin Koch, Ph.D.
Dr. Kevin Koch, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
359.40K
+1.74%
Dr. Joanne M. Donovan, M.D., Ph.D.
Dr. Joanne M. Donovan, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
21.49K
+32.17%
Dr. Behrad Derakhshan, Ph.D.
Dr. Behrad Derakhshan, Ph.D.
Chief Operating Officer
Chief Operating Officer
20.36K
+20.89%
Dr. Badreddin Edris, Ph.D.
Dr. Badreddin Edris, Ph.D.
Independent Director, Co-Founder
Independent Director, Co-Founder
19.82K
--
Dr. Jonathan D. (Jon) Root, M.D.
Dr. Jonathan D. (Jon) Root, M.D.
Independent Director
Independent Director
15.63K
--
Dr. Jonathan C. Fox, M.D., Ph.D.
Dr. Jonathan C. Fox, M.D., Ph.D.
Independent Director
Independent Director
11.42K
+5.15%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
OrbiMed Advisors, LLC
14.50%
RA Capital Management, LP
8.47%
Perceptive Advisors LLC
6.22%
Baker Bros. Advisors LP
5.85%
BlackRock Institutional Trust Company, N.A.
5.13%
Other
59.83%
Accionistas
Accionistas
Proporción
OrbiMed Advisors, LLC
14.50%
RA Capital Management, LP
8.47%
Perceptive Advisors LLC
6.22%
Baker Bros. Advisors LP
5.85%
BlackRock Institutional Trust Company, N.A.
5.13%
Other
59.83%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
25.70%
Investment Advisor/Hedge Fund
22.72%
Private Equity
21.28%
Investment Advisor
15.06%
Venture Capital
14.86%
Research Firm
1.38%
Individual Investor
0.50%
Pension Fund
0.21%
Bank and Trust
0.16%
Participación institucional
Actualizado: lun., 24 de feb
Actualizado: lun., 24 de feb
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
379
105.11M
110.49%
-2.65M
2024Q4
367
101.45M
106.62%
-4.12M
2024Q3
338
103.17M
110.02%
-3.61M
2024Q2
297
103.29M
110.57%
-1.75M
2024Q1
271
99.64M
106.68%
+5.45M
2023Q4
244
81.22M
115.32%
+5.36M
2023Q3
218
69.97M
110.26%
-9.47M
2023Q2
215
71.14M
112.43%
-5.61M
2023Q1
210
68.18M
108.02%
-8.97M
2022Q4
198
68.18M
108.11%
-5.86M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
OrbiMed Advisors, LLC
15.02M
15.86%
--
--
Dec 31, 2024
RA Capital Management, LP
8.91M
8.5%
--
--
Dec 31, 2024
Perceptive Advisors LLC
5.16M
4.93%
+2.48M
+92.31%
Feb 13, 2025
Baker Bros. Advisors LP
6.16M
5.88%
+315.88K
+5.41%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
5.36M
5.12%
+9.02K
+0.17%
Dec 31, 2024
Novo Holdings A/S
5.00M
4.77%
-549.90K
-9.91%
Dec 31, 2024
Janus Henderson Investors
4.98M
4.76%
+425.42K
+9.33%
Dec 31, 2024
Paradigm BioCapital Advisors LP
4.74M
4.52%
+245.00K
+5.45%
Jan 27, 2025
The Vanguard Group, Inc.
4.46M
4.25%
-49.21K
-1.09%
Dec 31, 2024
Cormorant Asset Management, LP
3.41M
3.25%
--
--
Dec 31, 2024
Ver más
ETFs relacionados
Actualizado: vie., 6 de jun
Actualizado: vie., 6 de jun
Nombre
Proporción
iShares Neuroscience and Healthcare ETF
2.21%
SPDR S&P Pharmaceuticals ETF
2.03%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.61%
ALPS Medical Breakthroughs ETF
1.12%
iShares U.S. Pharmaceuticals ETF
0.42%
Virtus LifeSci Biotech Clinical Trials ETF
0.38%
Federated Hermes MDT Small Cap Core ETF
0.34%
First Trust Multi-Manager Small Cap Opportunities ETF
0.18%
iShares Health Innovation Active ETF
0.17%
Invesco Nasdaq Biotechnology ETF
0.14%
Ver más
iShares Neuroscience and Healthcare ETF
Proporción2.21%
SPDR S&P Pharmaceuticals ETF
Proporción2.03%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción1.61%
ALPS Medical Breakthroughs ETF
Proporción1.12%
iShares U.S. Pharmaceuticals ETF
Proporción0.42%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.38%
Federated Hermes MDT Small Cap Core ETF
Proporción0.34%
First Trust Multi-Manager Small Cap Opportunities ETF
Proporción0.18%
iShares Health Innovation Active ETF
Proporción0.17%
Invesco Nasdaq Biotechnology ETF
Proporción0.14%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
